Established two years ago, the startup uses gesture sensing and other behavioural health metrics to determine when a user is eating a meal, providing real-time insights into eating habits.
Medtronic did not disclose financial details of the transaction but said the deal will have no impact on its earnings per share in the fiscal year 2020.
Medtronic plans to integrate Klue’s technology into its Personalized Closed Loop (PCL) insulin pump system.
Currently, Medtronic’s PCL insulin pump system is under development, designed to automate the delivery of insulin in a real-time, personalised and user-friendly manner.
Medtronic anticipates that the acquisition will strengthen the development of PCL technology, which received breakthrough designation from the FDA in February.
Medtronic advanced insulin management division president Alejandro Galindo said: “Bringing Klue and their unique meal detection capabilities into our organisation will accelerate our progress to help people with diabetes live with greater freedom and better health.
“Based on our learnings from a first-generation hybrid closed loop system around the importance of simplifying diabetes management, we believe the Personalized Closed Loop system will be transformational for diabetes management, and the integration of the Klue technology helps clears the path to a true hands-free closed-loop system.”
Furthermore, the company plans to leverage Klue’s technology to boost analytics and insights for its continuous glucose monitor (CGM) technology to help patients who use multiple daily injections to manage their diabetes.
In June, the University of Virginia’s (UVA) Center for Diabetes Technology (CDT) licensed Klue’s gesture sensing and behavioural analytics software for a proposed clinical trial to further diabetes treatment.
The acquisition of Klue follows Medtronic’s purchase of US-based surface technology company Titan Spine in June.